Journal: Biomolecules

Article Title: Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies

doi: 10.3390/biom11081200

Figure Lengend Snippet: Treatment strategy with chemotherapy (GEMOX) and tomotherapy. In trial 1 , patients received chemotherapy with gemcitabine + oxaliplatin (GEMOX) for 2 months, then radiotherapy (RT; 25 Gy in 5 fractions, starting 15 days after last cycle), then GEMOX again for 2 months and were subsequently evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received chemotherapy for an additional 2 months with GEMOX or gemcitabine alone, at the discretion of the investigator, and further RT (15 Gy in 3 fractions). In trial 2 , patients received GEMOX for 2 months, then RT (35 Gy in 7 fractions, starting 15 days after the 4th cycle), then GEMOX for an additional 2 months and were evaluated for surgery. Potentially resectable patients underwent surgery, while unresectable responders received further cycles of GEMOX or gemcitabine alone, at the discretion of the investigator, as maintenance therapy.

Article Snippet: In conclusion, GEMOX plus helical tomotherapy is a feasible multimodal strategy in LAPC, with a good safety profile and promising results in terms of survival and resection rate.

Techniques:

Journal: Biomolecules

Article Title: Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies

doi: 10.3390/biom11081200

Figure Lengend Snippet: Treatment strategy with chemotherapy (GEMOX) and tomotherapy. In trial 1 , patients received chemotherapy with gemcitabine + oxaliplatin (GEMOX) for 2 months, then radiotherapy (RT; 25 Gy in 5 fractions, starting 15 days after last cycle), then GEMOX again for 2 months and were subsequently evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received chemotherapy for an additional 2 months with GEMOX or gemcitabine alone, at the discretion of the investigator, and further RT (15 Gy in 3 fractions). In trial 2 , patients received GEMOX for 2 months, then RT (35 Gy in 7 fractions, starting 15 days after the 4th cycle), then GEMOX for an additional 2 months and were evaluated for surgery. Potentially resectable patients underwent surgery, while unresectable responders received further cycles of GEMOX or gemcitabine alone, at the discretion of the investigator, as maintenance therapy.

Article Snippet: We performed a pooled analysis, including an exploratory analysis for prognostic and predictive factors, of two phase 2 trials including 73 patients with LAPC, treated with gemcitabine and oxaliplatin (GEMOX) and hypofractionated tomotherapy.

Techniques:

Journal: Biomolecules

Article Title: Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies

doi: 10.3390/biom11081200

Figure Lengend Snippet: Maximum toxicity in 73 patients treated with GEMOX + tomotherapy.

Article Snippet: We performed a pooled analysis, including an exploratory analysis for prognostic and predictive factors, of two phase 2 trials including 73 patients with LAPC, treated with gemcitabine and oxaliplatin (GEMOX) and hypofractionated tomotherapy.

Techniques: